Navigation Links
UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation
Date:11/1/2007

WORCESTER, Mass.Investigators from the University of Massachusetts Medical School (UMMS) will investigate the causes of type 1 diabetes with dual grants from the Juvenile Diabetes Research Foundation (JDRF) and The Iacocca Foundation. The grants, of $150,000 each, will support the research efforts of the UMMS Heat Shock Protein Consortium. Directed by Aldo A. Rossini, MD, the William and Doris Krupp Professor of Medicine and professor of medicine and molecular medicine, the Heat Shock Protein Consortium brings together a unique group of scientists with diverse expertise in the basic sciences.

The innovation and synergy of the Consortium has already provided a mechanism for interaction and productivity in the field of science, explained Dr. Rossini. This synergy, we believe, will permit a new area of discovery by bringing together viewpoints of basic cell biology that are now focusing on the understanding of the pathogenesis of type 1 diabetes.

Heat shock proteins (Hsp) are essential proteins that protect the cell from a wide variety of environmental stresses. However, recent studies have demonstrated that altered Hsp function is associated with the development of a number of diseases, including type 1 diabetes. This funding will provide support for a number of innovative studies across a variety of departments and disciplines that aim to understand the Hsp abnormalities that may lead to the development and progression of type 1 diabetes.

We are committed to supporting young investigators in their development into diabetes-related careers and this important funding will foster creative approaches to the question of the role of cellular stress and autoimmune diabetes, explained Consortium investigator Dale L. Greiner, PhD, professor of medicine.

Better understanding the pathogenesis of diabetes will help accelerate the pace of science leading to cures and treatments for type 1 diabetes and its complications across a range of research areas, said Richard A. Insel, MD, Executive Vice President for Research at JDRF. Were thrilled to be partnering with The Iacocca Foundation to fund this important science at the University of Massachusetts Medical School.

Specific laboratories and their respective projects supported by the grants include:

  • Rita Bortell, PhD, associate professor of medicineThe role of endoplasmic reticulum (ER) stress in immune cell functions and during pathogenesis of autoimmune diabetes
  • Stephen J. Doxsey, PhD, professor of molecular medicine, biochemistry & molecular pharmacology and cell biologyThe novel role of centrosome proteins in insulin secretion and cellular stress
  • Dale L. Greiner, PhD, professor of medicineThe role of ER stress in islet transplantation
  • Gregory J. Pazour, PhD, associate professor of molecular medicineThe role of the pancreatic beta cell cilium in diabetes
  • Fumihiko Urano, MD, assistant professor of molecular medicineThe role of ER stress in autoimmune diabetes

Were excited about this partnership, said Iaccoca Foundation Executive Director Dana Ball. Our mission is to explore every possible avenue to find a cure for type 1 diabetes and we see incredible promise in the innovative approach UMass is taking.


'/>"/>

Contact: Kelly Bishop
kelly.bishop@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related medicine news :

1. Chancellor Of UMass Medical School Resigns Due to Health Reasons
2. NIH Funds the Development of National Consortium of Universities
3. Autism Gene Identified by Yale and Global Consortium
4. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
5. Scientists Awarded Appropriately For Contribution Towards Medical Research
6. Lifespan And Height Interlinked With Juvenile Diseases.
7. Psychiatric disorders among juveniles
8. Migraine & Juvenile stroke could be associated
9. Guidelines for treatment of juvenile idiopathic arthritis formulated
10. Type I diabetes or juvenile diabetes delays kidney disease onset
11. A New Technique For Treating Juvenile Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a full ... beneficiary of their ongoing community enrichment program. The current campaign fundraises for Angels ... are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide variety of organizations. DocuSyst provides a cloud hosted environment for ... Some installations include integration with various 3rd party applications using the FileHold web ...
(Date:2/8/2016)... MD (PRWEB) , ... February 08, 2016 , ... ... is excited to share this important news! AHCC and the Home Health and ... Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to address ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
(Date:2/8/2016)... Feb. 8, 2016  CTI BioPharma Corp. (CTI BioPharma) ... written communication from the U.S. Food and Drug Administration ... placed a partial clinical hold on the clinical studies ... application for pacritinib. This clinical hold impacts part of ... and will also affect planned clinical trials. ...
Breaking Medicine Technology: